Skip to main content
ATRO logo

ATRO · Astronics Corp

Track ATRO — free
$58.96 -1.35 (-2.24%) At close · Nov 13
Market Cap
$2.54B
Shares
43.13M
Volume · Nov 13 928.13K Avg daily vol (3M) 610.09K

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$58.96 Open$60.50 Day$56.66–61.38 Since split$52.88–93.45 Avg vol 30d604K Short int3.1M · 7.3% of shares · 5.5d Short vol44% Last earningsNov 10, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 12

The closing range begins at the captured split on Jun 15, 2026.

Up next

Feb 23, 2027 Est · unconfirmed · in 14 wks

Latest documents

2026
Nov 12
Quarterly report 10-Q FY2026 Q3, ended Oct 3
Quarterly report for FY2026 Q3 AI summary on its way
Revenue $271.68M ▲ 28.5% Net income $52.2M Diluted EPS $1.08
Nov 10
Earnings call
Record sales and expanding margins signal strong growth

Astronics Corporation reported third quarter sales of $271.7 million, up 28.5%, with adjusted EBITDA margin of 21.8%. It maintained 2026 revenue guidance of $1.02 billion to $1.04 billion and expects 2027 growth well north of 10%.

6 source passages
Welcome to the Astronics Corporation Third Quarter Fiscal Year 2026 Financial Results Conference Call. Sales reached $271.7 million, up 28.5% from the prior year period. Adjusted operating income was 18.8% of sales and adjusted EBITDA was 21.8% of sales. we are maintaining our 2026 Revenue Guide of $1.02 billion to $1.04 billion. More important, perhaps, are our expectations for 2027, which is right around the corner. Yeah, that's what we implied. That's what we meant. Something's done well north of 10%, exactly. Open the document at this passage
Nov 10
Current report 8-K
Third-quarter sales rise 28.5% to record $271.7 million

Astronics Corporation reported record third-quarter 2026 sales of $271.7 million, up 28.5%, operating income of $54.0 million and net income of $52.2 million. Backlog reached $780.0 million, while 2026 revenue guidance remained $1.02 billion to $1.04 billion.

Financial results
6 source passages
Astronics Corporation Reports Record Operating Income on 28% Sales Growth for Third Quarter 2026 Third quarter sales increased 28.5% to a record $271.7 million Record operating income was $54.0 million, or 19.9% of sales; adjusted operating income1 was $51.0 million, or 18.8% of sales Third quarter net income was $52.2 million, or $1.08 per diluted share; adjusted EBITDA1 was $59.3 million, or 21.8% of sales Quarterly bookings reached $271.1 million for book-to-bill of 1.00 and backlog was $780.0 million at quarter end; Aerospace book-to-bill at 1.05, over 1:1 for five consecutive quarters Maintaining 2026 revenue guidance of $1.02 billion to $1.04 billion Open the document at this passage
Aug 12
Quarterly report 10-Q FY2026 Q2, ended Jul 4
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $259.96M ▲ 27.0% Net income $35.06M ▲ 2568.2% Diluted EPS $0.75 ▲ 2400.0%
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$1.00B
Trailing 12 months
Net income (TTM)
$142.42M
Trailing 12 months
Revenue growth YoY
+28.5%
Year over year
Operating margin
15.7%
Trailing 12 months
P / E (TTM)
19.4
Trailing earnings · reciprocal yield 5.2%
FCF yield
2.4%
TTM · current market cap
Return on invested capital
28.6%
Trailing 12 months
Net cash
−$276.83M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+14.2%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
7.3%
Latest settlement · 5.5 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Nov 10, 2026
Q3 FY26

TL;DR. Astronics delivered record sales and operating income, broad-based Aerospace growth with record backlog, Test Systems improvement, $25.8 million of operating cash flow, debt reduction, lower planned capital expenditures, maintained 2026 guidance, and preliminary 2027 expectations well north of 10% growth. Risks include MV75 replanning, weaker Test Systems quarterly bookings, fourth-quarter margin and R&D pressure, supply-chain constraints, softer fourth-quarter revenue, and macroeconomic and oil-price headwinds.

Bullish
  • + Reported third-quarter results benefited from approximately $4.4 million of UK patent-related recoveries and an approximately $1 million favorable settlement.
Bearish
  • − The MV75 program is being rescheduled and replanned after previously operating on an accelerated schedule.
  • − Test Systems quarterly bookings were $12.8 million, producing a 0.49:1 book-to-bill ratio, although trailing-twelve-month bookings were $121.8 million at 1.41:1.
  • − Fourth-quarter margin will depend on sales mix, and R&D expense is expected to increase because of project timing.
  • − Supply-chain lead times are stretching and price escalation is being observed in some components.
  • − Fourth-quarter revenue is expected to step back modestly from the record third quarter despite a wide $255 million to $275 million guidance range.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Sell Momentum Weak Sentiment Bullish Fundamentals Excellent Quant / Vol Very High
Market backdrop VIX 19.3 · elevated Equity put/call 0.63
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −11%
below
Price vs 50-day avg −9%
below
RSI (14) 45
neutral
MACD trend Positive
52-week position 15%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Weak
1-month return −4%
trailing
6-month return −13%
trailing
YTD return +36%
this year
Relative strength −13%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $65 › 200d $66 — 200d above 50d
Institutional flow Accumulating
274 of 317 funds reported for Sep 30 · net +2.7M sh shares · +42 new
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
7.29% of shares out · ▼ -2.3% MoM · 5.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
317 holders — near 3-yr high, broad support
Squeeze score 66
elevated · 0–100
Fundamentals
Excellent
Revenue growth +8%
Y/Y
Gross margin 30%
expanding
EPS growth +276%
Y/Y
Free cash flow $60.5M
Buyback $41.5M
authorized
Balance sheet $316.3M
net debt
Quant / Vol
risk profile
Very High
Volatility 57%
annualized · 1-yr
Max drawdown −43%
past year
ATR 6.9%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 8 of last 8
Latest guidance · from the 8-K filed Nov 10, 2026
for the year
Revenue $1.02B – $1.04B
prior FY $862.13M midpoint +19.5% Y/Y
Fourth quarter
Sales $255M – $275M
prior qtr $271.68M midpoint −2.5% QoQ
over the next twelve months
Backlog at the end of the third quarter 83%
in 2026
Planned capital expenditures $25M – $30M
future
Future IEEPA tariff refunds $5M – $6M
Previous outlook earlier release · from the Earnings Call filed Aug 11, 2026

Still-open targets the latest release did not restate under the same label.

Revenue · full year 2026 $1.02B – $1.04B
Full-year CapEx · full year $40M – $45M
Prior guidance period ended · from the Earnings Call filed Aug 11, 2026
Third quarter sales · third quarter $265M – $275M
Guided vs delivered · last 8 settled
Third quarter sales third quarter
guided $265M – $275M
$271.68M In line
Second quarter sales second quarter
guided $245M – $250M
$259.96M Beat +5.0%
Revenue first quarter
guided $220M – $230M
$230.62M Beat +2.5%
Fourth quarter sales fourth quarter
guided $225M – $235M
$240.07M Beat +4.4%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell
3 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−11% Bearish
Price vs 50-day avg
−9% Bearish
RSI (14)
45 Neutral
MACD trend
Positive Bullish
52-week position
15% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $65 › 200d $66 — 200d above 50d
Institutional flow Accumulating
274 of 317 funds reported for Sep 30 · net +2.7M sh shares · +42 new
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
7.29% of shares out · ▼ -2.3% MoM · 5.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
317 holders — near 3-yr high, broad support
Price context
position in its range since split · 2026-06-15
Range low $53 Now $59 · 15% Range high $93
vs 200-day avg -11% vs 50-day avg -9%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Operating Margin 20.3% the three months ended July 4, 2026 filing —
Test Systems segment operating margin 2.6% Three Months Ended July 4, 2026 filing —
Adjusted Aerospace operating margin non-GAAP 21.4% Q2 2026 —
Adjusted EBITDA non-GAAP $51.5M Q2 2026 —
GAAP → non-GAAP reconciliation
GAAP Net income $35.06M
+$2.33M Interest expense
+$2.79M Income tax expense
+$6.34M Depreciation and amortization expense
+$2.26M Equity-based compensation expense
+$0K Simplification and restructuring initiatives
+$482K ERP implementation consulting expenses
+$0K Legal reserve, settlements and recoveries
+$1.87M Litigation-related legal expenses
+$0K Acquisition-related expenses
+$406K Warranty reserve
= Adjusted EBITDA $51.55M
Adjusted EBITDA margin non-GAAP 19.8% Q2 2026 —
Adjusted gross margin non-GAAP 33.6% Q2 2026 —
Adjusted operating margin non-GAAP 16.6% Q2 2026 —
Adjusted Test Systems margin non-GAAP 3.1% Q2 2026 —
Aerospace backlog $657.2M Q2 2026 —
Aerospace Book-to-bill ratio 1.02 Q2 2026 —
Aerospace bookings $243.1M Q2 2026 —
Aerospace segment operating margin 20.3% Q2 2026 —
Backlog $780.6M Q2 2026 —
Book-to-bill ratio 1.18 Q2 2026 —
Bookings $306.2M Q2 2026 —
Test Systems backlog $123.3M Q2 2026 —
Test Systems book-to-bill ratio 2.78 Q2 2026 —
Test Systems Bookings $63.05M Q2 2026 —
Test Systems segment bookings $63.1M Q2 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Aerospace & Defense — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ATRO
Astronics Corp
this stock
$2.54B — +8.4% — 7.3%
SPCX
Space Exploration Technologies Corp
$1.89T — — — 1.0%
GE
General Electric Co
$342.88B +7.7% +18.5% 38.3 1.2%
RTX
RTX Corp
$267.97B +8.3% +17.1% 32.2 1.0%
EADSF
Airbus SE
$178.35B -3.2% — — 0.1%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
329
% held
82.9%
Reported
274 of 317
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
273
View
Short & Settlement
Short Interest Falling
Shares short
3.1M
Days to cover
5.5d
Change
-75.1K sh
View
Short Volume
Short vol %
44%
As of
Nov 13, 2026
Short Total
View
Fails to Deliver
FTD shares
1
Value
$69
As of
Oct 7, 2026
View
Off-Exchange
Off-exchange %
39.7%
Week of
Oct 5, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$862.1M
Net income (FY)
$29.4M
EPS diluted
$0.68
View
Buybacks
Authorized
$41.5M
View
Filings
SEC Filings
Latest
10-Q
Filed
Nov 12, 2026
This year
17
View
Earnings & Events
Webcasts
Last webcast
Nov 12, 2026
View
Investor Relations
Latest news
Astronics Corporation Announces F…
Published
Oct 28, 2026
View

Performance

5D 20D 120D MTD YTD
ATRO +7.8% -4.2% -12.5% -0.7% +36.2%
SPY +2.6% -1.2% +0.5% -0.2% +10.6%
vs SPY +5.2% -3.0% -13.0% -0.5% +25.6%

Capital returns

Buyback program · as of Oct 3, 2026
Authorized
$41.50M
Spent (derived)
—
Remaining
—

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 8063 CUSIP 046433108 13F (30d) 258 filings 227 filers Visit website Investor relations